2402-2403 / 2953
CHHiP Study
3 x RT dose fractionations combined with
3–6 months of neoadjuvant hormone therapy
Patients (n=457) with localized prostate cancer
Randomized
74 Gy in 37 fractions
(7.5 weeks)
60 Gy in 20 fractions
(4 weeks)
57 Gy in 19 fractions
(3.8 weeks)
•
Safety results (median follow-up 50.5 months):
•
No increased toxicity for hypofractionated regimes at 2 years – efficacy results awaited
Dearnaley D, et al. Lancet Oncol 2012;13(1):43-54
41
RT dose
57Gy
60Gy
74Gy
Grade 2+ bowel toxicity
1.4%
3.6%
4.3%
Grade 2+ bladder toxicity
0%
2.2%
2.2%